You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
McKesson
Colorcon
Express Scripts

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

EZALLOR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Ezallor, and what generic alternatives are available?

Ezallor is a drug marketed by Sun Pharma Global and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in EZALLOR is rosuvastatin calcium. There are forty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the rosuvastatin calcium profile page.

US ANDA Litigation and Generic Entry Outlook for Ezallor

A generic version of EZALLOR was approved as rosuvastatin calcium by WATSON LABS INC on April 29th, 2016.

  Start Trial

Summary for EZALLOR
Drug patent expirations by year for EZALLOR
Drug Prices for EZALLOR

See drug prices for EZALLOR

Pharmacology for EZALLOR

US Patents and Regulatory Information for EZALLOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global EZALLOR rosuvastatin calcium CAPSULE;ORAL 208647-001 Dec 18, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global EZALLOR rosuvastatin calcium CAPSULE;ORAL 208647-004 Dec 18, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sun Pharma Global EZALLOR rosuvastatin calcium CAPSULE;ORAL 208647-002 Dec 18, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for EZALLOR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0521471 03C0043 France   Start Trial PRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106
0720599 C300688 Netherlands   Start Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NAT. REGISTRATION NO/DATE: RVG114002-004RVG 114008-010 2014110811; FIRST REGISTRATION: 13-9663 - 9665 20140724
0720599 300688 Netherlands   Start Trial PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ROSUVASTATINE; NATIONAL REGISTRATION NO/DATE: RVG114002-004 20140811; FIRST REGISTRATION: NO 13-9663 - 9665 20140724
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Mallinckrodt
McKinsey
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.